Ajay K. Singh, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematinics | 46 | 2023 | 282 | 11.880 |
Why?
|
| Anemia | 54 | 2022 | 1504 | 7.630 |
Why?
|
| Erythropoietin | 39 | 2023 | 719 | 7.470 |
Why?
|
| Renal Insufficiency, Chronic | 34 | 2024 | 2249 | 4.930 |
Why?
|
| Hemoglobins | 43 | 2023 | 1524 | 4.840 |
Why?
|
| Renal Dialysis | 34 | 2023 | 1799 | 3.130 |
Why?
|
| Kidney Diseases | 23 | 2019 | 2090 | 2.730 |
Why?
|
| Kidney Failure, Chronic | 27 | 2017 | 2477 | 2.570 |
Why?
|
| Epoetin Alfa | 19 | 2022 | 78 | 2.260 |
Why?
|
| Barbiturates | 5 | 2023 | 113 | 1.800 |
Why?
|
| Glycine | 4 | 2024 | 661 | 1.420 |
Why?
|
| Anemia, Iron-Deficiency | 5 | 2013 | 369 | 1.240 |
Why?
|
| Diabetic Nephropathies | 6 | 2024 | 972 | 1.130 |
Why?
|
| Nephrology | 4 | 2019 | 263 | 0.860 |
Why?
|
| Kidney | 10 | 2019 | 7045 | 0.810 |
Why?
|
| Recombinant Proteins | 22 | 2022 | 6520 | 0.810 |
Why?
|
| Iron | 6 | 2022 | 1790 | 0.690 |
Why?
|
| Ferritins | 6 | 2017 | 597 | 0.670 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 7995 | 0.660 |
Why?
|
| Bone Diseases, Metabolic | 3 | 2016 | 409 | 0.590 |
Why?
|
| Benzhydryl Compounds | 2 | 2024 | 915 | 0.570 |
Why?
|
| Iron Compounds | 2 | 2008 | 28 | 0.560 |
Why?
|
| Lupus Nephritis | 3 | 2005 | 317 | 0.530 |
Why?
|
| Proteinuria | 4 | 2013 | 606 | 0.450 |
Why?
|
| Hypertension, Renal | 1 | 2014 | 135 | 0.450 |
Why?
|
| Certification | 2 | 2019 | 418 | 0.440 |
Why?
|
| Renal Replacement Therapy | 2 | 2015 | 281 | 0.430 |
Why?
|
| Pathology | 1 | 2016 | 269 | 0.420 |
Why?
|
| Chronic Disease | 16 | 2010 | 9311 | 0.420 |
Why?
|
| Mass Screening | 3 | 2014 | 5424 | 0.410 |
Why?
|
| Ferric Compounds | 3 | 2008 | 378 | 0.400 |
Why?
|
| Humans | 111 | 2024 | 760617 | 0.390 |
Why?
|
| United States Food and Drug Administration | 3 | 2010 | 1661 | 0.390 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2008 | 27 | 0.390 |
Why?
|
| Fanconi Syndrome | 1 | 2011 | 34 | 0.380 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 534 | 0.370 |
Why?
|
| Saudi Arabia | 5 | 2016 | 210 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 12142 | 0.360 |
Why?
|
| Glomerular Filtration Rate | 8 | 2016 | 2178 | 0.360 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 413 | 0.350 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1813 | 0.350 |
Why?
|
| Kidney Tubules | 2 | 2009 | 449 | 0.350 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 671 | 0.340 |
Why?
|
| Calcium Compounds | 1 | 2009 | 38 | 0.330 |
Why?
|
| Cardiovascular Diseases | 15 | 2022 | 15498 | 0.330 |
Why?
|
| Biliary Tract Diseases | 1 | 2010 | 159 | 0.320 |
Why?
|
| Platelet Activation | 1 | 2012 | 646 | 0.310 |
Why?
|
| Middle Aged | 45 | 2022 | 220584 | 0.300 |
Why?
|
| Transferrin | 3 | 2008 | 283 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2010 | 10199 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3244 | 0.290 |
Why?
|
| Minerals | 1 | 2009 | 283 | 0.290 |
Why?
|
| Vitamin D | 3 | 2013 | 3302 | 0.290 |
Why?
|
| Male | 56 | 2022 | 360358 | 0.280 |
Why?
|
| Nephritis, Interstitial | 2 | 2008 | 155 | 0.270 |
Why?
|
| Kidney Glomerulus | 1 | 2009 | 568 | 0.270 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 1924 | 0.270 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2009 | 335 | 0.250 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 1551 | 0.250 |
Why?
|
| Female | 55 | 2022 | 392148 | 0.250 |
Why?
|
| India | 3 | 2020 | 2286 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2010 | 3680 | 0.250 |
Why?
|
| Prevalence | 10 | 2016 | 15689 | 0.250 |
Why?
|
| Societies, Medical | 2 | 2019 | 3900 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 7 | 2012 | 7389 | 0.240 |
Why?
|
| Treatment Outcome | 23 | 2022 | 64568 | 0.240 |
Why?
|
| Aged | 37 | 2022 | 169042 | 0.240 |
Why?
|
| Phosphates | 1 | 2008 | 769 | 0.240 |
Why?
|
| Erythropoiesis | 2 | 2023 | 684 | 0.230 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 666 | 0.230 |
Why?
|
| Research Design | 5 | 2024 | 6174 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2014 | 1935 | 0.230 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2371 | 0.220 |
Why?
|
| Injections, Intravenous | 5 | 2008 | 1376 | 0.220 |
Why?
|
| Heart Arrest | 1 | 2014 | 1513 | 0.220 |
Why?
|
| Heart Failure | 10 | 2024 | 11669 | 0.220 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1388 | 0.220 |
Why?
|
| Risk Factors | 20 | 2020 | 74115 | 0.220 |
Why?
|
| Nurse's Role | 1 | 2005 | 188 | 0.220 |
Why?
|
| Early Diagnosis | 3 | 2014 | 1185 | 0.220 |
Why?
|
| Cytokines | 2 | 2008 | 7373 | 0.220 |
Why?
|
| Drug Approval | 1 | 2010 | 812 | 0.210 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 1748 | 0.210 |
Why?
|
| Cost Savings | 1 | 2008 | 912 | 0.210 |
Why?
|
| Kidney Transplantation | 3 | 2009 | 4236 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1700 | 0.210 |
Why?
|
| Ibuprofen | 1 | 2003 | 229 | 0.200 |
Why?
|
| Glomerulonephritis | 1 | 2004 | 331 | 0.200 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 803 | 0.200 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2016 | 125 | 0.200 |
Why?
|
| Pandemics | 1 | 2022 | 8645 | 0.190 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 794 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2010 | 1160 | 0.190 |
Why?
|
| Granuloma | 1 | 2003 | 328 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2010 | 1297 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2012 | 2478 | 0.190 |
Why?
|
| Stroke | 9 | 2021 | 9712 | 0.190 |
Why?
|
| Testis | 1 | 2004 | 792 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 10754 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2007 | 1315 | 0.170 |
Why?
|
| Endoscopy | 1 | 2010 | 1851 | 0.170 |
Why?
|
| Prognosis | 8 | 2016 | 29600 | 0.170 |
Why?
|
| Albuminuria | 1 | 2023 | 655 | 0.170 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1624 | 0.170 |
Why?
|
| Ovary | 1 | 2004 | 959 | 0.170 |
Why?
|
| Tobacco, Smokeless | 1 | 2020 | 133 | 0.170 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2001 | 165 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2008 | 1589 | 0.160 |
Why?
|
| Fertility | 1 | 2004 | 769 | 0.160 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 11459 | 0.160 |
Why?
|
| Glucosides | 1 | 2023 | 512 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2689 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 680 | 0.150 |
Why?
|
| Risk Assessment | 11 | 2019 | 23972 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2009 | 2565 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 2218 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2010 | 2329 | 0.150 |
Why?
|
| Medicare | 4 | 2010 | 6765 | 0.150 |
Why?
|
| Hypertension | 4 | 2013 | 8529 | 0.140 |
Why?
|
| Infertility | 1 | 2004 | 654 | 0.140 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15251 | 0.140 |
Why?
|
| Adult | 23 | 2023 | 220969 | 0.140 |
Why?
|
| Contrast Media | 2 | 2008 | 5305 | 0.140 |
Why?
|
| Hematocrit | 2 | 2009 | 623 | 0.140 |
Why?
|
| Patients | 1 | 2023 | 906 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4433 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 376 | 0.130 |
Why?
|
| Biopsy | 5 | 2019 | 6762 | 0.130 |
Why?
|
| Hospital Mortality | 2 | 2014 | 5293 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 2190 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2012 | 2925 | 0.120 |
Why?
|
| Neoplasms | 2 | 2023 | 22131 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2010 | 2315 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2003 | 2331 | 0.110 |
Why?
|
| International Cooperation | 2 | 2019 | 1421 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 5146 | 0.110 |
Why?
|
| Blood Viscosity | 1 | 2013 | 124 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3164 | 0.110 |
Why?
|
| Age Factors | 4 | 2020 | 18381 | 0.100 |
Why?
|
| Data Collection | 1 | 2022 | 3315 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 4174 | 0.100 |
Why?
|
| Middle East | 1 | 2012 | 231 | 0.100 |
Why?
|
| United States | 10 | 2017 | 72272 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2012 | 15828 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 26049 | 0.090 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 678 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2214 | 0.090 |
Why?
|
| Metformin | 1 | 2019 | 906 | 0.090 |
Why?
|
| Double-Blind Method | 8 | 2022 | 12334 | 0.090 |
Why?
|
| Comorbidity | 3 | 2013 | 10505 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2014 | 532 | 0.090 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 161 | 0.090 |
Why?
|
| CD40 Ligand | 1 | 2012 | 521 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2010 | 4117 | 0.090 |
Why?
|
| Drug Costs | 2 | 2008 | 1183 | 0.080 |
Why?
|
| Program Development | 1 | 2016 | 1293 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2006 | 960 | 0.080 |
Why?
|
| P-Selectin | 1 | 2012 | 599 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 2152 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 460 | 0.080 |
Why?
|
| Iron, Dietary | 1 | 2010 | 148 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2010 | 122 | 0.080 |
Why?
|
| Cilazapril | 1 | 2008 | 3 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2022 | 54360 | 0.080 |
Why?
|
| Risk Reduction Behavior | 3 | 2011 | 1110 | 0.080 |
Why?
|
| Ferrosoferric Oxide | 1 | 2010 | 348 | 0.080 |
Why?
|
| Survival Rate | 3 | 2014 | 12719 | 0.080 |
Why?
|
| Inflammation | 1 | 2008 | 10760 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2008 | 63 | 0.080 |
Why?
|
| Ergocalciferols | 1 | 2009 | 110 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 59 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 3822 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 352 | 0.070 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 2561 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2013 | 2278 | 0.070 |
Why?
|
| Sclerosis | 1 | 2008 | 210 | 0.070 |
Why?
|
| Publication Bias | 1 | 2008 | 160 | 0.070 |
Why?
|
| Phosphorus | 1 | 2009 | 335 | 0.070 |
Why?
|
| Cardiac Output | 1 | 2010 | 831 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 4025 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 13245 | 0.070 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 1017 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3410 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2010 | 248 | 0.070 |
Why?
|
| Calcitriol | 1 | 2009 | 296 | 0.070 |
Why?
|
| Age Distribution | 1 | 2013 | 2871 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 361 | 0.070 |
Why?
|
| Organotechnetium Compounds | 1 | 2007 | 129 | 0.070 |
Why?
|
| Models, Biological | 1 | 2003 | 9461 | 0.070 |
Why?
|
| Polycythemia | 1 | 2008 | 124 | 0.070 |
Why?
|
| Patient Selection | 2 | 2010 | 4237 | 0.070 |
Why?
|
| Biological Availability | 1 | 2007 | 389 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2008 | 183 | 0.070 |
Why?
|
| Disease Progression | 4 | 2017 | 13495 | 0.070 |
Why?
|
| Leuprolide | 1 | 2008 | 312 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 650 | 0.070 |
Why?
|
| Awareness | 1 | 2010 | 649 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 992 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 4007 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 2650 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2009 | 10073 | 0.060 |
Why?
|
| Histology | 1 | 2004 | 16 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 312 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2016 | 80566 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2008 | 696 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2007 | 410 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 538 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 292 | 0.060 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 277 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 1483 | 0.060 |
Why?
|
| Iothalamic Acid | 1 | 2003 | 17 | 0.060 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2003 | 67 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1562 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2012 | 6338 | 0.060 |
Why?
|
| Nephrosis | 1 | 2003 | 43 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 426 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2690 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 12966 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6474 | 0.050 |
Why?
|
| Bone Diseases | 1 | 2007 | 418 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2008 | 636 | 0.050 |
Why?
|
| Ovum | 1 | 2004 | 187 | 0.050 |
Why?
|
| Adolescent | 6 | 2016 | 88234 | 0.050 |
Why?
|
| Probability | 1 | 2008 | 2475 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2008 | 937 | 0.050 |
Why?
|
| Nephritis | 1 | 2003 | 145 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 729 | 0.050 |
Why?
|
| Curriculum | 1 | 2016 | 3738 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1623 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 808 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2012 | 2595 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2004 | 472 | 0.050 |
Why?
|
| Sirolimus | 1 | 2009 | 1533 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2014 | 4470 | 0.050 |
Why?
|
| Sex Factors | 2 | 2013 | 10548 | 0.050 |
Why?
|
| Reference Values | 2 | 2013 | 4919 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 6305 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2014 | 41457 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 1517 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 58894 | 0.050 |
Why?
|
| Quality of Life | 4 | 2023 | 13347 | 0.050 |
Why?
|
| Algorithms | 3 | 2012 | 14018 | 0.050 |
Why?
|
| Morbidity | 1 | 2006 | 1750 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2001 | 71 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 1725 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2008 | 883 | 0.040 |
Why?
|
| Health Care Reform | 1 | 2010 | 1247 | 0.040 |
Why?
|
| Calcium | 2 | 2016 | 5717 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2014 | 6346 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2410 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2008 | 1185 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2010 | 8618 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1520 | 0.040 |
Why?
|
| Young Adult | 4 | 2017 | 59179 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2004 | 629 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 1031 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 9604 | 0.040 |
Why?
|
| Thrombosis | 2 | 2006 | 2943 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2010 | 5239 | 0.040 |
Why?
|
| Hospitalization | 3 | 2009 | 10704 | 0.040 |
Why?
|
| Calcinosis | 1 | 2008 | 1469 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4804 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1879 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 905 | 0.040 |
Why?
|
| Oocytes | 1 | 2004 | 1166 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2004 | 728 | 0.040 |
Why?
|
| Causality | 1 | 2005 | 1240 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 3979 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 12043 | 0.040 |
Why?
|
| Nucleosomes | 1 | 2002 | 487 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1670 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3206 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2016 | 42188 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2007 | 2049 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11069 | 0.040 |
Why?
|
| Length of Stay | 2 | 2014 | 6418 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2017 | 134 | 0.040 |
Why?
|
| Child | 4 | 2016 | 80079 | 0.040 |
Why?
|
| Acute Disease | 1 | 2008 | 7237 | 0.040 |
Why?
|
| Incidence | 2 | 2012 | 21337 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 1463 | 0.040 |
Why?
|
| Developing Countries | 1 | 2009 | 2867 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4341 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2009 | 9643 | 0.030 |
Why?
|
| Cause of Death | 2 | 2019 | 3683 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 39063 | 0.030 |
Why?
|
| Inpatients | 1 | 2008 | 2544 | 0.030 |
Why?
|
| Massachusetts | 1 | 2009 | 8833 | 0.030 |
Why?
|
| Education, Distance | 1 | 2019 | 259 | 0.030 |
Why?
|
| Oliguria | 1 | 2014 | 21 | 0.030 |
Why?
|
| Medicaid | 1 | 2008 | 2814 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4446 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2010 | 4789 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22148 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2007 | 2015 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20556 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 1896 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2002 | 2115 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 12447 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 39913 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2012 | 35 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2013 | 315 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7402 | 0.020 |
Why?
|
| Diuretics | 1 | 2014 | 611 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 5835 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 14648 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 943 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 1803 | 0.020 |
Why?
|
| Thailand | 1 | 2009 | 287 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1810 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13635 | 0.020 |
Why?
|
| Mortality | 1 | 2019 | 2899 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2459 | 0.020 |
Why?
|
| Animals | 2 | 2009 | 168201 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9476 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 2379 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 957 | 0.010 |
Why?
|
| Executive Function | 1 | 2013 | 1391 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2006 | 577 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6224 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2630 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2008 | 1415 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 1972 | 0.010 |
Why?
|
| Memory | 1 | 2013 | 2192 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2007 | 407 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5866 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1643 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2222 | 0.010 |
Why?
|
| Sepsis | 1 | 2014 | 2585 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1663 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9313 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7050 | 0.010 |
Why?
|
| Disease Management | 1 | 2009 | 2506 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2006 | 2768 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2007 | 2361 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14591 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 36152 | 0.010 |
Why?
|